New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life when compared to baseline Clinically important improvements seen for all.
VANCOUVER, British Columbia, Aug. 08, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian.
VANCOUVER, British Columbia, Aug. 02, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and.
VANCOUVER, British Columbia, June 06, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th. | June 6, 2023